Articles tagged with Drug Resistance
Scientists at James Cook University warn that concurrent training can impair endurance development if recovery is not accounted for. They propose a new approach to mitigate resistance training-induced fatigue, which can affect athletes' performance several days after a single session.
A Massachusetts General Hospital research team found that anti-angiogenic drugs induce a microenvironment that suppresses immune systems actions, allowing tumors to grow. Developing a potential strategy to overcome this mechanism, the researchers identified CX3CL1 as an attractive target for immunotherapy.
A national survey of rural physicians found significant barriers to prescribing buprenorphine for opioid use disorder, including time constraints and lack of mental health support services. The study calls for tailored strategies to address these barriers and support physicians in providing Buprenorphine Maintenance Treatment.
Currently available drugs may be used alone or in combination to treat infectious diseases, addressing a pressing need due to slow development of new therapies. Non-profit entities and private industry collaboration is crucial for discovering novel interventions to combat drug-resistant pathogens.
Women are at greater risk of cardiovascular disease due to longer lifespan and differences in drug absorption, distribution, and metabolism compared to men. The European Society of Cardiology recommends sex-specific guidelines for cardiovascular drugs to minimize adverse reactions.
New research from the University of Pennsylvania School of Medicine finds that lenvatinib improves overall survival rates in older thyroid cancer patients who are resistant to standard radioiodine treatment. The drug is well-tolerated and has a significant impact on patient outcomes.
Researchers at LSTM and partners have developed a molecule, E209, effective against parasites with artemisinin resistance. The fully synthetic molecule is designed to be fast-acting and slowly eliminated, offering hope as a single-dose cure.
Research finds that tulip bulbs from the Netherlands are carrying a fungal pathogen resistant to key antifungal therapy, Voriconazole. The discovery raises concerns for immunocompromised patients and highlights the need for vigilance in preventing the spread of resistance.
The researchers discovered that major biological signalling circuits can be made to resonate when driven at their resonant frequency, allowing for the control of cell signalling pathways. This method has potential relevance in the treatment of diseases and could guide the discovery of new therapeutic approaches.
The FDA approves brigatinib as a second-line therapy for ALK-positive non-small cell lung cancer, demonstrating a 54% response rate and 12.9-month progression-free survival. Brigatinib's longer control duration compared to other next-generation ALK inhibitors suggests its broader spectrum of coverage against resistance mechanisms.
Researchers discovered a key molecule VCP linked to Human Cytomegalovirus replication, which can be blocked by chemicals to stop the virus from multiplying. This approach could lead to more powerful therapies and reduce the risk of resistance.
The Critical Path Institute and Translational Genomics Research Institute will sequence at least 12,000 tuberculosis bacteria isolates from around the world to better understand drug resistance. The partnership aims to develop personalized medicine options for patients with drug-resistant TB.
Researchers have identified a genetic signature associated with resistance in triple negative breast cancer, which can be reversed after a period of treatment cessation. This discovery may lead to personalized chemotherapy strategies and improved treatment outcomes.
Researchers have proven that understanding and predicting tumor resistance can lead to additional treatment options in the clinical setting. By studying non-small cell lung cancer cells, the team found that some drugs are more susceptible to other drugs, even when resistant to a single drug.
Dr. Katerina A. Politi has made significant contributions to the understanding and treatment of EGFR mutant lung cancer. Her research has led to a paradigm-shift in the diagnosis and treatment of lung cancer, including the early adoption of molecular profiling.
A new and inexpensive treatment option for drug-resistant malaria has been developed using plant therapy made from dried leaves of the Artemisia annua plant. The treatment, known as DLA, was tested on 18 critically ill patients in a Congo clinic and showed a 100% recovery rate, including a five-year-old child who had lapsed into a coma.
Researchers identify detailed structure of protein complex used by bacteria to detect environmental changes and adapt to them. This discovery sheds light on how bacteria develop resistance to antibiotics.
A combination of a PARP inhibitor and a kinase inhibitor showed significant tumor shrinkage in 36% of patients with platinum-resistant ovarian cancer, a surprising improvement over solo PARP inhibitor treatment. The treatment was well-tolerated, with four patients discontinuing due to toxicity.
Scientists at Liverpool School of Tropical Medicine have created a new way to screen potential treatments for Tuberculosis (TB), which may reduce treatment duration from six months to weeks.
Researchers at Mass General Hospital identified novel resistance mechanisms in patients with liver tumors receiving FGFR inhibitor treatment. The study found that different mutations within individual patients and across multiple samples could confer resistance, highlighting the need for more effective treatments.
Trichomonosis is a common infectious cause of large bowel diarrhea in cats, characterized by 'cow pie' consistency and mucus/blood in faeces. The infection is caused by the protozoan Tritrichomonas foetus, which can be transmitted from cat to cat via the faecal-oral route.
Scientists have found that two immune system molecules, interleukin 1 beta (IL1β) and tumor necrosis factor alpha (TNFα), may drive drug resistance in estrogen-driven breast cancers by modifying the shape of the estrogen receptor. This finding could lead to novel therapeutic approaches.
Researchers identified a secondary pathway to reactivate EthA enzyme in resistant TB strains, boosting treatment efficacy. The combination of SMARt-420 and ethionamide effectively treated resistant TB strains, reducing bacterial load in mouse lungs.
Researchers at Cardiff University have devised a new way of creating the leading anti-malarial drug artemisinin, which could reduce market fluctuations in the supply chain and help study resistance to the drug. The new method bypasses several key steps in the production process, achieving the desired outcome in just four steps.
Researchers have created a detailed atomic map of the frontline antimalarial drug mefloquine, showing how its structure could be tweaked to increase effectiveness. The study aims to create a more targeted and safer treatment by redesigning the drug's molecular machinery.
Researchers have created a precise atomic map of the frontline antimalarial drug mefloquine, showing how its structure could be changed to make it more effective. The study provides a route to develop new treatments with fewer resources and potentially reduced side effects.
Researchers at Mayo Clinic have identified a specific protein implicated in drug resistance, as well as a possible therapeutic tool. By engineering a peptide that blocks the activity of another protein ERK, the team found that it can prevent chemotherapy resistance and tumor growth.
Research reveals that expression levels of ABCB1 and ABCG2 transporters significantly affect cell resistance to Dasatinib. Lower transporter expression levels mediate lower resistance, implying a potential breakthrough for targeted cancer treatment.
Research reveals that only one in five patients with resistant hypertension are taking all their prescribed medications, while 20% are not taking any. The study found that adherence to medication greatly affects the ability to assess the value of another treatment, and patients can take steps to prevent high blood pressure from remaini...
Researchers at Ohio State University Comprehensive Cancer Center have identified a mechanism by which cancer cells develop resistance to FGFR inhibitors. By inhibiting the regulatory protein Akt, they found that cell proliferation, migration, and invasion could be slowed in lung and bladder cancer cells.
Scientists at The Wistar Institute have identified an anti-aging gene that inhibits a protein involved in metastatic progression and resistance to targeted therapies. Activating this gene with an anti-diabetic drug may provide a promising adjuvant therapy for older melanoma patients.
Scientists have detected an artemisinin-resistant malaria parasite originating from West Africa for the first time in Africa, posing a significant threat to malaria control efforts. The finding confirms that the parasite carries a new mutation in the Kelch13 gene, which is the primary driver of resistance in Southeast Asia.
Researchers aim to develop novel treatments and preventative medicines to assist with malaria eradication and elimination, replacing ineffective current drugs that are losing efficacy.
Researchers discovered that malaria parasites produce HMBPP, which stimulates red blood cells to release carbon dioxide and volatile compounds attracting malaria mosquitoes. The parasite uses this system to transfer from one host to another, making it harder to control the spread of malaria.
Researchers identify factors determining when containment or aggressive treatment is best, providing new guidance for physicians and patients. Containment strategies can prolong treatment life and improve outcomes in certain situations.
A new mathematical analysis provides guidance for treating infections and tumors with drug resistance, suggesting that containment may extend effective life and improve patient outcomes in some cases. The study identifies two main factors influencing the choice between containment and aggressive treatment.
Researchers are studying the effectiveness of two treatment options for children with Kawasaki disease who resist initial therapy. The study aims to compare the impact of IVIG and infliximab on preventing heart damage in these patients.
Dr. Timothy Anderson received a 5-year, $4.6 million MERIT Award to study drug resistance in malaria parasites and develop effective treatment strategies. The award supports his efforts to understand the genetic determinants of resistance and apply powerful gene editing technologies.
Mass drug administration programmes have significantly increased treatment for bilharzia, killing an estimated 280,000 people annually. Praziquantel MDA programmes are effective but long-term effects and resistance to the drug are largely unknown.
A new approach to treating tuberculosis could significantly reduce treatment time and improve patient outcomes. Researchers identified an effective four-drug regimen that kills TB bacteria in the lungs and cures mice up to four times faster than current treatments.
A study published in The New England Journal of Medicine found that extensively drug-resistant tuberculosis (XDR TB) is spread through person-to-person contact in the KwaZulu-Natal province, South Africa. This epidemic highlights the need for effective infection control and treatment measures to prevent further spread.
Researchers found a wide variety of CRE species and genetic traits enabling resistance, with traits transferring easily among species. The findings suggest that CRE may be transmitting from person to person asymptomatically, highlighting the need for increased genomic surveillance.
Researchers have solved the atomic structure of HIV's intasome, a key piece of machinery that integrates virus into human DNA. The discovery provides structural clues informing the development of new HIV drugs and sheds light on mechanisms of viral resistance.
Researchers found that tumors shed between seven and 18 mutations in neoantigen-coding genes after developing resistance to immunotherapy drugs. This phenomenon could lead to new ways to improve current cancer immunotherapies.
A new study reveals that cancer cells can develop resistance to proteasome inhibitors by suppressing the expression of proteasome subunits, leading to a broadly altered cell state with unique vulnerabilities. This finding may expose opportunities for targeted therapies that can be effective against diverse cancers.
Researchers identified gene mutations associated with steroid resistance in pediatric T-cell acute lymphoblastic leukemia, leading to poor clinical outcomes. A new therapeutic approach targeting individual signaling proteins restored steroid sensitivity in leukemic cells from patients.
Researchers at IRB Barcelona have discovered 10 new drug combinations that show high synergy in treating breast cancer, outperforming individual treatments. These combinations aim to overcome treatment resistance by attacking tumour cells from multiple angles.
A study published in Cell Reports found that glioblastoma cells with different resistance levels to therapy and radiation are linked to disease outcomes. Researchers identified a continuum of cells with varying resistance levels, which may enable the development of targeted therapies.
Researchers have developed a rapid test to monitor drug resistance in hookworms, which can cause disease and stunted growth. The new test uses short nucleotide polymorphisms to detect drug-resistant mutations in as little as 1% of a sample, taking only 60 minutes.
Researchers at the Weizmann Institute of Science have identified a promising new combination therapy for triple negative breast cancer, which inhibits tumor growth and survival while preventing drug resistance. The therapy targets EGFR and PYK2 molecules, leading to a more potent therapeutic effect than inhibiting either molecule alone.
Researchers found that blocking tumor interferon pathway with a JAK inhibitor improves checkpoint inhibitor drugs and bypasses the need for combinations, which often come with serious side effects. The study suggests a new approach to addressing cancer immunotherapies' limitations.
Researchers at the University of Southampton have characterised the molecular mechanisms behind idelalisib's effectiveness in treating chronic lymphocytic leukaemia. The study found that the drug disrupts survival signals and prevents tumour cell communication, leading to cancer cell death.
A study investigated infectious disease mortality trends in the US from 1980 to 2014, revealing overall and infectious disease mortality decreased until 1995, then leveled off. The introduction of antiretroviral therapy for HIV/AIDS led to a decline in overall and HIV/AIDS mortality rates.
Researchers investigated resistance to antiangiogenic therapies using animal models, finding inconsistent definitions of treatment failure. The study emphasizes the need for improved methodology to accurately predict alternative strategies that benefit patients.
A newly identified protein, NTR2, has been discovered that activates drugs like delamanid against leishmaniasis. This finding holds promise for developing more effective treatments for the disease.
Scientists discovered genetic markers linked with piperaquine resistance in Plasmodium parasites, allowing health officials to monitor the spread of resistance and guide treatment decisions. The emergence of piperaquine resistance in Cambodia threatens global efforts to eliminate malaria.
Scientists have identified two genetic markers associated with piperaquine resistance in malaria parasites, allowing for early detection and alternative treatment options. The markers are linked to increased production of plasmepsin enzymes, which the parasite uses to digest human blood.
Researchers at MUSC Hollings Cancer Center discover a mechanism conferring resistance to AML drugs and develop a ceramide-based therapeutic that reactivates mitophagy, killing drug-resistant cancer cells. The treatment has clinical appeal due to its specificity towards cancer cells.
Researchers found no differences in HIV drug resistance between women using dapivirine and placebo rings in the ASPIRE trial. The dapivirine ring was safe and helped protect against HIV, with an overall risk reduction of 27%.
A MGH team found that treating metastatic colorectal cancer with antiangiogenic drugs increases extracellular matrix components and stiffness, contributing to treatment resistance. Antiangiogenic therapy also attracts suppressor immune cells, reducing the immune response against tumors.